The Effect of Sacubitril/Valsartan (LCZ – 696) on Symptoms and Hospitalization in Patients with Acute HFrEF Due to Acute Coronary Syndrome

Abstract

Background & Aim: The aim of the research was to study the effect of LCZ-696 in patients with heart failure minus the acute ejection segment minus the ejection segment resulting from acute coronary syndrome in terms of the number and duration of hospitalizations, symptom control and improvement of systolic function.

Materials and Methods: A Prospective Cohort study, performed on 50 patients diagnosed with  acute heart failure reduce EF resulting from acute coronary syndrome at Al-Assad and Al-Mouwasat University Hospitals in Damascus during the period from 15/May/2019 until 15/December/2020. The relationship between patient data (age, sex, severity of symptoms, systolic function of the heart muscle, diastolic function of the heart muscle, hospitalization and its duration) was studied, in order to know the effect of LCZ-696 in patients with heart failure minus acute ejection segment minus ejection segment resulting from coronary syndrome in terms of number of hospitalizations, duration of hospitalization, symptoms control and improvement of systolic function.

Results: We found that the p-value of the relationship between the use of LCZ-696 medication and the improvement of systolic and echogenic function is 0.000, that is, less than 0.05, and therefore there is a statistical relationship between them, and it was also associated with an improvement in clinical symptoms from an improvement in the degree of dyspnea according to NYHA classification (P=0.012), It was associated with an improvement in the laboratory values of NT-PRO-BNP (P=0.000).

Conclusions: Echoic systolic function improves with improvement in clinical symptoms of NYHA-classified dyspnea in patients with heart failure minus acute ejection segment minus ejection segment resulting from acute coronary syndrome with LCZ-696.